Anil Karbhari Shinde

This inventor holds 37 USPTO granted patents and 5 published patent applications, plus 34 CIPO patents and 36 EPO patents, primarily in CNS Disorder Treatment. Top assignees: Suven Life Sciences Limited, Suven Sciences Limited, Other. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anil Karbhari Shinde. Retrieved from https://idiyas.com/inventor/anil-karbhari-shinde

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 5)

% Patents Active = 75.7

CIPO Patents = 34 (Patent Applications = 8)

EPO Patents = 36 (Patent Applications = 38)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 27(Granted Patents)

Location History:

Andhra Pradesh, IN (2014 - 2017)
Telangana, IN (2019 - 2022)
Hyderabad, IN (2011 - 2023)

Company Filing History:

35 out of 55

Suven Life Sciences Limited

patents

1 out of 1

Suven Sciences Limited

patent

1 out of 834,513

Other

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

CNS Disorders

5-HT Receptor Agonists

Muscarinic M1 Modulators

Histamine H3 Ligands

Piperidine Compounds

Piperazine Compounds

Acrylamide Compounds

Polycyclic Amides

Aryl Sulfonamide

Benzoisothiazole

Fluoropiperidine

Pyrrolo-Pyridazine Derivatives

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721846 - Methods for treating behavioral and psychological symptoms in patients with dementia (2026-09-01),

2. 12391698 - Substituted piperidines and piperazines and methods for the treatment of CNS disorders (2025-08-19),

3. 12338236 - Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders (2025-06-24),

4. 12285421 - Uses of a 5-HT4 receptor agonist (2025-04-29),

5. 12275746 - Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists (2025-04-14),

6. 12156871 - Substituted azacycles as muscarinic M1 receptor positive allosteric modulators (2024-12-03),

7. 12122779 - Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators (2024-10-22),

8. 11622967 - Method of treatment with histamine-3 receptor inverse agonist (2023-04-11),

9. 11458135 - Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors (2022-10-04),

10. 11278530 - Polycyclic amides as muscarinic M1 receptor positive allosteric modulators (2022-03-22),

11. 11253514 - Triple combination of pure 5-HTreceptor antagonists, acetylcholinesterase inhibitors and NMDA receptor antagonist (2022-02-22),

12. 11234979 - Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators (2022-02-01),

13. 11116764 - Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist (2021-09-14),

14. 11040026 - Muscarinic M1 receptor positive allosteric modulators (2021-06-22),

15. 10973831 - Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists (2021-04-13),

Certainly! Here is an article about inventor Anil Karbhari Shinde:

Title: The Visionary Inventor: Anil Karbhari Shinde's Journey of Innovation

Introduction: Anil Karbhari Shinde, a renowned inventor based in Hyderabad, India, has made significant strides in shaping the future of technology with his passion for innovation and dedication to excellence. His relentless pursuit of pushing boundaries has solidified his reputation as a visionary inventor in the field.

Latest Patents:

1. **Method of Treatment with Histamine-3 Receptor Inverse Agonist:** Anil Karbhari Shinde's latest invention revolutionizes the treatment of various sleep-related disorders, such as narcolepsy and obstructive sleep apnea, by utilizing a histamine-3 receptor (H3R) inverse agonist. This method offers new possibilities for managing sleep and vigilance disorders associated with several medical conditions.

2. **Combination of Pure 5-HT6 Receptor Antagonists with Acetylcholinesterase Inhibitors:** Shinde's patent introduces a novel approach to treating cognitive disorders by combining pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors. This innovative combination opens avenues for more effective therapies in cognitive healthcare.

Career Highlights: With an impressive portfolio of 30 patents to his name, Anil Karbhari Shinde continues to push the boundaries of innovation in the technology sector. His contributions have not only advanced the field but also paved the way for novel solutions to complex healthcare challenges.

Collaborations: Throughout his career, Shinde has collaborated with esteemed professionals in the industry, including Venkateswarlu Jasti and Ramakrishna Nirogi. These collaborations have led to groundbreaking inventions and fostered an environment of creativity and shared expertise.

Conclusion: Anil Karbhari Shinde's unwavering commitment to innovation and his groundbreaking patents have positioned him as a trailblazer in the technology landscape. His relentless pursuit of excellence and collaborative spirit continue to inspire the next generation of inventors and pave the way for a future driven by revolutionary advancements in technology.

If you need further information or assistance, feel free to ask!

Profile summary based on public USPTO records.